Is Circulation a Good Journal? Impact, Scope, and Fit

Circulation has a specific editorial identity that many submitting authors misread. It is a clinical cardiovascular journal. The AHA flagship publishes landmark clinical trials, major cardiovascular epidemiology, and translational research with direct practice implications. It is NOT the home for basic cardiovascular science (that is Circulation Research, IF 17.7) or narrowly subspecialty clinical work (that routes to JACC family journals or Circulation subspecialty titles).

The Clinical Perspective box that accompanies every original research article is the journal's screening tool in miniature. If you cannot write two sentences explaining what a clinician should do differently after reading your paper, the manuscript is probably not a Circulation paper.

Desk rejection runs 55-60%, and it comes fast (median 17 days). Editors are screening for two things: clinical significance and study design rigor. Clinical significance means the findings change how cardiologists manage a common condition or substantially revise understanding of a major cardiovascular mechanism. Study design rigor means multicenter trials, large prospective cohorts, or well-powered designs with defined endpoints.

Is Circulation a good journal?

Yes. Circulation is the flagship journal of the American Heart Association with a 2024 impact factor of 38.6. It is one of the top two cardiovascular journals in the world, alongside the European Heart Journal (IF 35.6).

What is Circulation's acceptance rate?

Approximately 8% of submitted manuscripts are accepted. The desk rejection rate is roughly 55-60%. Among papers that reach peer review, acceptance runs around 20%. Median time to first decision is 17 days.

What is the difference between Circulation and Circulation Research?

Circulation (IF 38.6) publishes clinical cardiovascular research: trials, clinical epidemiology, and translational work with direct practice implications. Circulation Research (IF 17.7) publishes basic and translational cardiovascular science. If your paper is primarily mechanistic without a clinical bridge, Circulation Research is the better target.

Is Circulation better than JACC?

Circulation (IF 38.6, AHA) and JACC (IF 21.0, ACC) are the two leading US cardiovascular journals. Circulation has a higher IF and broader cardiovascular scope. JACC skews more toward clinical cardiology practice. The choice depends on whether the finding has broad cardiovascular relevance (Circulation) or is more practice-specific (JACC).

In our pre-submission review work with manuscripts targeting Circulation, three patterns generate the most consistent desk rejections among the papers we analyze.

Absent or underdeveloped Clinical Perspective content. Circulation's author guidelines require every original research paper to include a Clinical Perspective box answering two questions: what is new, and what is clinically relevant. We observe that manuscripts where this box is completed with generic statements ("this study advances understanding of cardiovascular disease") rather than concrete clinical implications ("these findings suggest that patients with X should be screened for Y before Z") are desk-rejected at high rates. The Clinical Perspective is not a formality; it is the journal's primary triage filter.

Single-center or underpowered study designs claiming broad generalizability. Circulation's scope emphasizes research with "direct implications for cardiovascular medicine" at a population level. SciRev author reports consistently note that single-center observational studies and underpowered trials are among the most common desk-rejection reasons. We find manuscripts that acknowledge their single-center limitation in the discussion but frame the abstract and conclusions as if the findings apply broadly. Editors catch this mismatch at the screen stage.

Basic science without a clinical bridge. Circulation and Circulation Research (IF 17.7) have distinct editorial scopes that authors frequently conflate. Circulation's guidelines state explicitly that the journal publishes "clinical and translational research" with "direct implications for patient care." We see mechanistic manuscripts with strong molecular or cellular data but only a small translational bridge experiment landing at Circulation when Circulation Research is the appropriate target. The distinction is not about quality but about whether the primary contribution is a clinical finding or a mechanistic one.

SciRev author-reported data confirms Circulation's 17-day median to first decision. A Circulation clinical scope check can assess Clinical Perspective completeness and study design framing before editors do.

Journal editorial capacity fluctuates. Submissions during major conference seasons face longer reviewer turnaround. End-of-year submissions may sit longer during holiday periods. New IF announcements (June each year) can temporarily increase submissions to journals whose IF rose.

For selective journals, the practical advice is: submit when the manuscript is ready, not when the calendar seems favorable. A paper that is scientifically complete and properly targeted will succeed regardless of timing. A paper with gaps will fail regardless of when you submit.

A Circulation submission readiness check evaluates fit independently of timing.